Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Atef, Halabi"'
Autor:
Magda S. C. Fontes, Jasper Dingemanse, Atef Halabi, Monika Tomaszewska-Kiecana, Patricia N. Sidharta
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-7 (2022)
Abstract The effect of moderate hepatic impairment on the pharmacokinetics (PK), safety, and tolerability of the dual endothelin receptor antagonist aprocitentan was clinically investigated as 25% of aprocitentan is cleared through the liver. Aprocit
Externí odkaz:
https://doaj.org/article/3dc6220942ca44c5abcd448b14fe4443
Autor:
Thomas Forst, Chantal Mathieu, Francesco Giorgino, David C. Wheeler, Nikolaos Papanas, Roland E. Schmieder, Atef Halabi, Oliver Schnell, Marina Streckbein, Katherine R. Tuttle
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-15 (2022)
Abstract Background Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with type 2 diabetes. With the incidence of type 2 diabetes continuing to inc
Externí odkaz:
https://doaj.org/article/62020e62af414e208c77428994711e7b
Autor:
Uta Schilling, Chih‐Hsuan Hsin, Stephane Delahaye, Andreas Krause, Hauke Wuelfrath, Atef Halabi, Jasper Dingemanse
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 8, Pp 1906-1915 (2022)
Abstract Selatogrel is a potent and selective reversible P2Y12 receptor antagonist in development for early treatment of acute myocardial infarction via subcutaneous (s.c.) self‐injection. Selatogrel is almost exclusively eliminated via the hepatob
Externí odkaz:
https://doaj.org/article/e72d62fa217e4ed5aacade759ddf6999
Autor:
Thomas N. Kakuda, Atef Halabi, Gernot Klein, Madhu Sanga, Carine Guinard‐Azadian, Monika Kowalik, Katja Nedoschinsky, Julius Nangosyah, Emmanuel Njumbe Ediage, Vera Hillewaert, Peter Verboven, Ivo Goris, Jan Snoeys, Martyn Palmer, Michael Biermer
Publikováno v:
The Journal of Clinical Pharmacology. 63:732-741
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cba13bd19fd72820553526ce012f9e1d
https://doi.org/10.1002/jcph.2214
https://doi.org/10.1002/jcph.2214
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 44:619-628
Finerenone (BAY 94-8862) is a selective, nonsteroidal mineralocorticoid receptor antagonist. The aim of this study was to assess the effect of mild or moderate hepatic impairment on the pharmacokinetics, safety and tolerability of finerenone. The stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a86ba5a18feb09e6fe8899fe9203918e
https://doi.org/10.1007/s13318-019-00547-x
https://doi.org/10.1007/s13318-019-00547-x
Publikováno v:
European journal of clinical pharmacology. 76(3)
Lucerastat is an orally available glucosylceramide synthase inhibitor with a potential to provide substrate reduction therapy for Fabry patients independent of their α-galactosidase A genotype. In humans, lucerastat is mainly eliminated as unchanged
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::477cb5cc86846718a0d13746ef3acd3f
https://pubmed.ncbi.nlm.nih.gov/31836927
https://pubmed.ncbi.nlm.nih.gov/31836927
Autor:
Marcus-Hillert Schultze-Mosgau, Atef Halabi, Torsten Zimmermann, Sandra Ligges, Kai Riecke, Niladri Chattopadhyay
Publikováno v:
British journal of clinical pharmacology. 85(9)
AIMS The study objective was to evaluate the pharmacokinetics of the selective progesterone receptor modulator vilaprisan in participants with hepatic impairment. Additionally, the safety and tolerability of vilaprisan were investigated. METHODS In t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2545aca4097de1605bf816787edaf6f0
https://pubmed.ncbi.nlm.nih.gov/32677245
https://pubmed.ncbi.nlm.nih.gov/32677245
Publikováno v:
Molecular Genetics and Metabolism. 132:S52
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15ba4677fe9db2f1c78c9b5804096022
https://doi.org/10.1016/j.ymgme.2020.12.114
https://doi.org/10.1016/j.ymgme.2020.12.114
Publikováno v:
Clinical Pharmacology in Drug Development. 5:488-501
Finerenone (BAY 94-8862) is a nonsteroidal mineralocorticoid receptor antagonist in development for the treatment of diabetic kidney disease. This observational trial compared the pharmacokinetics of a single oral dose of finerenone 10 mg (immediate-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b87bec0ed3aec133319bdf64326d7341
https://doi.org/10.1002/cpdd.263
https://doi.org/10.1002/cpdd.263
Autor:
David Schnell, Dietmar Gansser, Raimund Külzer, Anne Weber, Gudrun Wallenstein, Sven Wind, Sabrina Wiebe, Atef Halabi, Anja Conrad
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Afatinib is an oral irreversible ErbB-Family Blocker indicated for treatment of patients with EGFR mutation positive advanced non-small cell lung cancer. This trial assessed whether renal impairment influences the pharmacokinetics and safety of afati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cdf6732a9d268c5227adfc3be9caa05
http://europepmc.org/articles/PMC5423921
http://europepmc.org/articles/PMC5423921